Atacicept

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
024620072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
OBJECTIVES Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side… (More)
Is this relevant?
2014
2014
BACKGROUND Depletion of B lymphocytes is associated with suppression of inflammatory activity in multiple sclerosis. We aimed to… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
INTRODUCTION Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
OBJECTIVE To assess the efficacy, safety, and biologic activity of atacicept in tumor necrosis factor antagonist-naive patients… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE Atacicept is a recombinant fusion protein that binds and neutralizes B lymphocyte stimulator and a proliferation… (More)
Is this relevant?
2008
2008
Atacicept, a soluble recombinant fusion protein of the human immunoglobulin (Ig) G(1) Fc and the extracellular domain of the… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2008
2008
Atacicept is a recombinant fusion protein containing the extracellular ligand-binding portion of the transmembrane activator and… (More)
Is this relevant?
2008
2008
APRIL (a proliferation-inducing Ligand) and BLyS/BAFF (B-lymphocyte stimulator/B-cell-activating factor of the TNF (tumor… (More)
  • table 1
  • figure 3
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To assess the safety and tolerability of atacicept in patients with systemic lupus erythematosus (SLE) and the biologic… (More)
Is this relevant?
2007
2007
Atacicept, a recombinant fusion protein, blocks the activity of BLyS (a B-lymphocyte stimulator) and APRIL (a proliferation… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?